A powerful Grand Rounds presentation by Dr. Richard Amerling challenges the foundation of evidence-based medicine, exposing how rigid guidelines, financial conflicts, and pharma influence have replaced real clinical judgment—often at the expense of patient care.

Read about this class:

In a provocative installment of the Zelenko Memorial Grand Rounds, Dr. Richard Amerling—an experienced nephrologist and academic—delivered a powerful critique of today’s medical landscape, zeroing in on the unintended consequences of so-called evidence-based medicine (EBM). Though the term evokes a sense of scientific rigor, Dr. Amerling argues that the current implementation of EBM has eroded clinical judgment and replaced thoughtful medical care with rigid, industry-influenced protocols.

The Illusion of Scientific Neutrality

Dr. Amerling opened by sharing his background and his recent visit to Belgium, where he was reminded of the strength of a real scientific education—one that values critical thinking. He contrasted this with the current medical system, which, he contends, now prioritizes guideline adherence over individualized care.

The central claim? Guidelines touted as “evidence-based” are rarely tested against traditional clinical methods, and worse, are often shaped by financial interests.

Dietary Guidelines: A Case Study in Failure

Dr. Amerling dissected the evolution of the U.S. dietary guidelines since the 1970s—highlighting how they coincided with a nationwide surge in obesity, diabetes, and metabolic disorders. He pointed to specific recommendations, such as replacing saturated fats with vegetable oils and limiting sodium, which he considers scientifically unsupported and even harmful.

According to Amerling, these guidelines serve more as industry cover than health guidance, masking dangerous advice behind buzzwords like “nutrient-dense” or “individualized care”—while pushing low-fat dairy, high-carb grain-based diets, and demonizing salt and saturated fat.

Diabetes and Cardiovascular Disease: Misguided Priorities

Dr. Amerling criticized the diabetes treatment guidelines for focusing almost exclusively on glycemic control—a strategy he says offers little cardiovascular benefit and increases the risk of hypoglycemia. He noted that while newer dietary strategies like intermittent fasting and low-carb diets have started to appear in guidelines, they are still treated as afterthoughts.

Similarly, he warned against the widespread prescription of statins, particularly for people with type 2 diabetes, calling it a practice driven by pharmaceutical interests rather than clear scientific benefit.

Chronic Kidney Disease: Ignoring Root Causes

In reviewing kidney disease guidelines, Dr. Amerling took aim at the push for low-protein, plant-based diets in patients with chronic kidney disease (CKD)—an approach he says has been disproven by landmark studies like the MDRD trial. He emphasized that the real driver of CKD is metabolic syndrome, which can often be reversed with a low-carb, high-fat diet.

He also raised concerns about the growing use of SGLT2 inhibitors and ACE inhibitors in CKD patients, pointing out that these drugs can lead to acute kidney failure, especially when combined with common medications like calcium channel blockers.

The Bigger Picture: Pharma-Based Medicine

Throughout his presentation, Dr. Amerling made it clear: what’s sold as evidence-based medicine is often little more than pharma-based medicine. Clinical experience and scientific reasoning are routinely sidelined in favor of one-size-fits-all treatment protocols. These rigid guidelines, he warns, endanger patients and punish doctors who dare to think independently.

Is There Hope?

While cautious, Dr. Amerling did offer a glimmer of optimism. He pointed to growing public skepticism, potential political shifts, and the resurgence of ethical principles like informed consent as signs of a brewing transformation. He emphasized that true medical progress depends not on more guidelines, but on restoring integrity, clinical insight, and patient-first care.